EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Trial of Endovascular Therapy for Acute Ischemic Stroke with Large Infarct

Xiaochuan Huo, Gaoting Ma, Xu Tong, Xuelei Zhang, Yuesong Pan iD, Thanh N Nguyen iD, Guangxiong Yuan, Hongxing Han, Wenhuo Chen, Ming Wei, Jiangang Zhang, Zhiming Zhou und 47 weitere

New England Journal of Medicine · 06.04.2023 · 388 (14) · 1272-1283

DOI: 10.1056/nejmoa2213379 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 06.04.2023. Verfasst von Xiaochuan Huo und 58 weiteren Autor:innen. Beteiligte Einrichtung: From Interventional Neuroradiology, Department of Neurology (X.H., G.M., X.T., X. Zhang, Y.P., F.G., N.M., D.M., L.S., X.S., X.L., Y.D., G. Luo, Z.M.…. Hauptthemen laut MEDLINE: Brain Ischemia, Cerebral Infarction, Endovascular Procedures, Ischemic Stroke. Die Arbeit wurde bisher 918-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Covidien Healthcare International Trading (Shanghai), Johnson & Johnson MedTech, Genesis MedTech.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The role of endovascular therapy for acute stroke with a large infarction has not been extensively studied in differing populations. METHODS: We conducted a multicenter, prospective, open-label, randomized trial in China involving patients with acute large-vessel occlusion in the anterior circulation and an Alberta Stroke Program Early Computed Tomography Score of 3 to 5 (range, 0 to 10, with lower values indicating larger infarction) or an infarct-core volume of 70 to 100 ml. Patients were randomly assigned in a 1:1 ratio within 24 hours from the time they were last known to be well to undergo endovascular therapy and receive medical management or to receive medical management alone. The primary outcome was the score on the modified Rankin scale at 90 days (scores range from 0 to 6, with higher scores indicating greater disability), and the primary objective was to determine whether a shift in the distribution of the scores on the modified Rankin scale at 90 days had occurred between the two groups. Secondary outcomes included scores of 0 to 2 and 0 to 3 on the modified Rankin scale. The primary safety outcome was symptomatic intracranial hemorrhage within 48 hours after randomization. RESULTS: A total of 456 patients were enrolled; 231 were assigned to the endovascular-therapy group and 225 to the medical-management group. Approximately 28% of the patients in both groups received intravenous thrombolysis. The trial was stopped early owing to the efficacy of endovascular therapy after the second interim analysis. At 90 days, a shift in the distribution of scores on the modified Rankin scale toward better outcomes was observed in favor of endovascular therapy over medical management alone (generalized odds ratio, 1.37; 95% confidence interval, 1.11 to 1.69; P = 0.004). Symptomatic intracranial hemorrhage occurred in 14 of 230 patients (6.1%) in the endovascular-therapy group and in 6 of 225 patients (2.7%) in the medical-management group; any intracranial hemorrhage occurred in 113 (49.1%) and 39 (17.3%), respectively. Results for the secondary outcomes generally supported those of the primary analysis. CONCLUSIONS: In a trial conducted in China, patients with large cerebral infarctions had better outcomes with endovascular therapy administered within 24 hours than with medical management alone but had more intracranial hemorrhages. (Funded by Covidien Healthcare International Trading [Shanghai] and others; ANGEL-ASPECT ClinicalTrials.gov number, NCT04551664.).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain IschemiaCerebral InfarctionEndovascular ProceduresIschemic StrokeThrombectomyHumansChinaFibrinolytic AgentsIntracranial HemorrhagesProspective StudiesStrokeTreatment Outcome

Substanzen

Fibrinolytic Agents

Autor:innen und Institutionen

  • From Interventional Neuroradiology, Department of Neurology (X.H., G.M., X.T., X. Zhang, Y.P., F.G., N.M., D.M., L.S., X.S., X.L., Y.D., G. Luo, Z.M.), and the Departments of Neurosurgery (M.L., H. He, A.L., Jingbo Zhan…

ORCID-Profile: Yuesong Pan, Thanh N Nguyen, Lian Liu, Jing Jing, Yongjun Wang

Förderung

  • Covidien Healthcare International Trading (Shanghai)
  • Johnson & Johnson MedTech
  • Genesis MedTech
  • Shanghai HeartCare Medical Technology
  • Covidien Healthcare International Trading (Shanghai) Co., Ltd.
  • Genesis MedTech (Shanghai) Co.,Ltd. & Shanghai HeartCare Medical Technology Co., Ltd.

Zitieren

APA

Huo, X., Ma, G., Tong, X., Zhang, X., Pan, Y., Nguyen, T. N., Yuan, G., Han, H., Chen, W., Wei, M., Zhang, J., Zhou, Z., Yao, X., Wang, G., Song, W., Cai, X., Nan, G., Li, D., Wang, A. Y., …, & ANGEL-ASPECT Investigators (2023). Trial of Endovascular Therapy for Acute Ischemic Stroke with Large Infarct. New England Journal of Medicine, 388(14), 1272-1283. https://doi.org/10.1056/nejmoa2213379

Vancouver

Huo X, Ma G, Tong X, Zhang X, Pan Y, Nguyen TN, et al. Trial of Endovascular Therapy for Acute Ischemic Stroke with Large Infarct. New England Journal of Medicine. 2023;388(14):1272-1283. doi:10.1056/nejmoa2213379

BibTeX
@article{Huo2023,
  author = {Huo, Xiaochuan and Ma, Gaoting and Tong, Xu and Zhang, Xuelei and Pan, Yuesong and Nguyen, Thanh N and Yuan, Guangxiong and Han, Hongxing and Chen, Wenhuo and Wei, Ming and Zhang, Jiangang and Zhou, Zhiming and Yao, Xiaoxi and Wang, Guoqing and Song, Weigen and Cai, Xueli and Nan, Guangxian and Li, Di and Wang, A Yi-Chou and Ling, Wentong and Cai, Chuwei and Wen, Changming and Wang, En and Zhang, Liyong and Jiang, Changchun and Liu, Yajie and Liao, Geng and Chen, Xiaohui and Li, Tianxiao and Liu, Shudong and Li, Jinglun and Gao, Feng and Ma, Ning and Mo, Dapeng and Song, Ligang and Sun, Xuan and Li, Xiaoqing and Deng, Yiming and Luo, Gang and Lv, Ming and He, Hongwei and Liu, Aihua and Zhang, Jingbo and Mu, Shiqing and Liu, Lian and Jing, Jing and Nie, Ximing and Ding, Zeyu and Du, Wanliang and Zhao, Xingquan and Yang, Pengfei and Liu, Liping and Wang, Yilong and Liebeskind, David S and Pereira, Vitor M and Ren, Zeguang and Wang, Yongjun and Miao, Zhongrong and ANGEL-ASPECT Investigators, ANGEL-ASPECT Investigators},
  title = {Trial of Endovascular Therapy for Acute Ischemic Stroke with Large Infarct},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {388},
  number = {14},
  pages = {1272--1283},
  doi = {10.1056/nejmoa2213379}
}
Kostenlos starten →